Apogee Therapeutics, Inc.

APGE

Apogee Therapeutics, Inc.

APGE

Insider Sentiment (TTM):

Last Purchase:2024-12-12Last Sale:2026-06-22Shares Purchased (TTM):0Shares Sold (TTM):2,156,345

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:66,431,969Shares Outstanding:69,668,439Institutional Ownership Pct.:95.35%

Earnings Market Reaction:

Filing Date:2026-05-11Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Biological Products, (No Diagnostic Substances)

AMGN GILD SCLX BIIB MRNA RVMD

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Assets
Assets Current
Cash	-	-	-	-	-	-	-	-	-	-	-	125
Cash Equivalents At Carrying Value	452	132	108	124	107	142	119	307	485	118	188	-
Marketable Securities Current	608	599	419	381	406	379	407	369	331	277	235	-
Prepaid Expense And Other Assets Current	14	11	13	11	8	9	8	6	4	3	4	6
Assets Current	1,074	741	540	516	522	530	534	682	821	398	426	131
Marketable Securities Noncurrent	198	173	62	116	168	210	228	113	-	-	-	-
Property Plant And Equipment Net	5	6	6	6	6	2	1	1	1	0	-	-
Operating Lease Right Of Use Asset	8	9	10	11	12	11	12	4	2	2	-	-
Other Assets Noncurrent	9	9	9	9	7	0	1	0	0	0	-	-
Assets	1,294	937	626	658	714	754	776	801	824	401	426	131
Liabilities And Stockhold…
Liabilities Current
Temporary Equity Carrying Amount Attributable To P…	-	-	-	-	-	-	-	-	-	-	-	177
Common Unit Issuance Value	-	-	-	-	-	-	-	-	-	-	-	2
Accounts Payable Current	1	1	0	6	2	1	2	6	4	2	1	11
Operating Lease Liability Current	3	4	4	4	4	3	3	2	1	1	-	-
Accrued Liabilities Current	-	-	-	-	-	-	28	17	16	17	16	6
Liabilities Current	33	28	34	32	33	29	33	25	22	21	17	18
Liabilities Noncurrent
Operating Lease Liability Noncurrent	5	5	6	7	8	9	9	2	1	1	-	-
Liabilities	38	33	40	38	41	37	42	27	22	21	17	18
Limited Liability Company…
Temporary Equity Shares Authorized	-	-	-	-	-	-	-	-	-	-	-	65
Temporary Equity Shares Issued	-	-	-	-	-	-	-	-	-	-	-	65
Temporary Equity Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	65
Temporary Equity Liquidation Preference	-	-	-	-	-	-	-	-	-	-	-	169
Common Stock Value	0	0	0	0	0	0	0	0	0	-	-	-
Additional Paid In Capital	1,892	1,465	1,078	1,046	1,034	1,022	970	964	958	503	501	-
Accumulated Other Comprehensive Income Loss Net Of…	-1	1	1	1	1	1	3	-0	-0	0	0	-
Retained Earnings Accumulated Deficit	-636	-562	-492	-427	-361	-306	-239	-190	-156	-124	-92	-71
Members Equity	1,256	904	586	619	673	717	734	774	801	380	409	-64
Liabilities And Stockholders Equity	1,294	937	626	658	714	754	776	801	824	401	426	131
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	400	400	400	400	400	400	400	400	400	400	400	400
Series Preferred Units	-	-	-	-	-	-	-	-	-	0	0	20
Common Stock Shares Issued	75	69	60	60	60	59	59	58	58	51	51	-
Shares Outstanding	75	68	59	59	58	58	57	57	56	24	48	-
Series B Preferred Units	-	-	-	-	-	-	-	-	-	0	34	12
Common Unit Authorized	-	-	-	-	-	-	-	-	-	0	0	5
Common Unit Issued	-	-	-	-	-	-	-	-	-	0	5	5
Common Unit Outstanding	-	-	-	-	-	-	-	-	-	0	5	5
Preferred Stock Shares Authorized	-	-	-	-	-	-	-	-	-	10	10	-
Preferred Stock Par Or Stated Value Per Share	-	-	-	-	-	-	-	-	-	0	0	-
Preferred Stock Shares Issued	-	-	-	-	-	-	-	-	-	0	0	-
Preferred Stock Shares Outstanding	-	-	-	-	-	-	-	-	-	0	0	-

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	2.74%	57.10%	-	-	-	-	-	-	-	-	-	-
2025	3.54%	19.91%	-4.62%	9.29%	15.09%	63.32%	35.19%	33.49%	15.40%	9.74%	20.72%	14.45%
2024	-20.94%	-27.90%	-16.42%	6.28%	22.54%	22.56%	-12.87%	-16.70%	-27.88%	26.54%	17.39%	25.77%
2023	-	-	-	-10.54%	-26.96%	-21.56%	31.94%	69.29%	113.76%	12.06%	-20.52%	-19.01%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 50+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 50+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	32.59	26.57	15.86	16.36	15.82	18.55	16.39	27.70	38.08	19.38	24.82	7.42
Quick Ratio	32.16	26.17	15.49	16.02	15.57	18.23	16.13	27.47	37.87	19.24	24.62	7.10
Working Capital	1.04B	713.45M	506.05M	484.57M	488.57M	501.15M	501.87M	657.24M	799.06M	377.85M	409.24M	113.05M
Leverage & Debt
Debt to Equity	0.03	0.04	0.07	0.06	0.06	0.05	0.06	0.03	0.03	0.06	0.04	0.16
Debt Ratio	0.03	0.04	0.06	0.06	0.06	0.05	0.05	0.03	0.03	0.05	0.04	0.13
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-
Per Share Metrics
Diluted EPS TTM	-3.94	-4.22	-4.32	-4.07	-3.53	-3.30	-2.80	-2.32	-2.31	-	-	-
Free Cash Flow Per Share TTM	-3.44	-3.90	-4.12	-3.95	-3.32	-3.12	-2.37	-1.96	-2.13	-	-	-
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-
Growth Metrics
Net Income Growth (1Y)	33.70%	40.46%	59.35%	81.41%	76.94%	-	-	-	-	-	-	-
EPS Growth (1Y)	11.68%	27.74%	53.99%	75.47%	52.60%	-	-	-	-	-	-	-
Valuation Metrics
P/E TTM	-21.35	-17.91	-9.21	-10.68	-10.59	-13.73	-20.96	-16.97	-28.73	-	-	-
P/B TTM	4.67	5.07	3.98	4.10	3.23	3.49	4.54	2.87	4.16	1.84	2.15	-
Market Cap	5.86B	4.58B	2.34B	2.54B	2.17B	2.50B	3.34B	2.22B	3.34B	698.66M	878.23M	-
Enterprise Value	5.41B	4.45B	2.23B	2.41B	2.07B	2.36B	3.22B	1.92B	2.85B	580.05M	689.96M	-
Calculated Values
Free Cash Flow TTM	-239.69M	-236.91M	-241.88M	-230.90M	-193.14M	-172.33M	-134.37M	-110.97M	-106.75M	-	-	-
Net Debt	-451.80M	-131.55M	-107.91M	-124.49M	-106.92M	-142.08M	-119.07M	-307.59M	-485.75M	-118.61M	-188.27M	-125.07M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-22Sale

Owner: Dambkowski, Carl

Title: Chief Medical Officer

Shares: 26,400

Price/Share: $132.60

Value: $3,500,640.00

Shares Owned: 179,248

Relationship: Officer

Ownership: Direct

2026-06-22Sale

Owner: Henderson, Michael Thomas

Title: Chief Executive Officer

Shares: 80,000

Price/Share: $132.54

Value: $10,603,200.00

Shares Owned: 1,015,987

Relationship: Director,Officer

Ownership: Direct

2026-06-10Sale

Owner: Henderson, Michael Thomas

Title: Chief Executive Officer

Shares: 20,000

Price/Share: $84.59

Value: $1,691,800.00

Shares Owned: 1,095,987

Relationship: Director,Officer

Ownership: Direct

2026-06-03Sale

Owner: Dambkowski, Carl

Title: Chief Medical Officer

Shares: 5,500

Price/Share: $78.71

Value: $432,905.00

Shares Owned: 205,648

Relationship: Officer

Ownership: Direct

2026-05-13Sale

Owner: Henderson, Michael Thomas

Title: Chief Executive Officer

Shares: 20,000

Price/Share: $82.32

Value: $1,646,400.00

Shares Owned: 1,115,987

Relationship: Director,Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-22	Dambkowski, Carl	Officer	Chief Medical Officer	Direct	Sale	26,400	132.60	$3,500,640.00	179,248	4
2026-06-22	Henderson, Michael Thomas	Director,Officer	Chief Executive Officer	Direct	Sale	80,000	132.54	$10,603,200.00	1,015,987	4
2026-06-10	Henderson, Michael Thomas	Director,Officer	Chief Executive Officer	Direct	Sale	20,000	84.59	$1,691,800.00	1,095,987	4
2026-06-03	Dambkowski, Carl	Officer	Chief Medical Officer	Direct	Sale	5,500	78.71	$432,905.00	205,648	4
2026-05-13	Henderson, Michael Thomas	Director,Officer	Chief Executive Officer	Direct	Sale	20,000	82.32	$1,646,400.00	1,115,987	4
2026-05-06	Dambkowski, Carl	Officer	Chief Medical Officer	Direct	Sale	5,500	84.26	$463,430.00	207,023	4
2026-05-01	Henderson, Jane	Officer	Chief Financial Officer	Direct	Sale	2,000	82.26	$164,520.00	173,371	4
2026-04-16	Henderson, Jane	Officer	Chief Financial Officer	Direct	Sale	2,000	90.00	$180,000.00	175,371	4
2026-04-08	Henderson, Michael Thomas	Director,Officer	Chief Executive Officer	Direct	Sale	20,000	83.58	$1,671,600.00	1,132,987	4
2026-04-01	Dambkowski, Carl	Officer	Chief Medical Officer	Direct	Sale	5,500	85.18	$468,490.00	208,398	4
2026-04-01	Henderson, Jane	Officer	Chief Financial Officer	Direct	Sale	2,000	84.96	$169,920.00	177,371	4
2026-03-25	Henderson, Jane	Officer	Chief Financial Officer	Direct	Sale	2,000	85.00	$170,000.00	179,371	4
2026-03-11	Henderson, Michael Thomas	Director,Officer	Chief Executive Officer	Direct	Sale	20,000	74.99	$1,499,800.00	1,152,987	4
2026-03-04	Dambkowski, Carl	Officer	Chief Medical Officer	Direct	Sale	5,500	71.86	$395,230.00	209,773	4
2026-03-02	Henderson, Jane	Officer	Chief Financial Officer	Direct	Sale	2,000	69.95	$139,900.00	181,371	4
2026-02-11	Henderson, Michael Thomas	Director,Officer	Chief Executive Officer	Direct	Sale	20,000	63.89	$1,277,800.00	1,172,987	4
2026-02-04	Dambkowski, Carl	Officer	Chief Medical Officer	Direct	Sale	5,500	66.88	$367,840.00	211,148	4
2026-02-02	Henderson, Jane	Officer	Chief Financial Officer	Direct	Sale	2,000	66.08	$132,160.00	183,371	4
2026-01-22	Harwin, Peter Evan, Fairm…	Director	-	Indirect	Sale	1,750,000	76.30	$133,525,000.00	298,647	4
2026-01-14	Henderson, Michael Thomas	Director,Officer	Chief Executive Officer	Direct	Sale	20,000	81.47	$1,629,400.00	1,192,987	4
2026-01-07	Dambkowski, Carl	Officer	Chief Medical Officer	Direct	Sale	18,700	78.53	$1,468,511.00	212,523	4
2026-01-06	Henderson, Jane	Officer	Chief Financial Officer	Direct	Sale	2,000	80.00	$160,000.00	185,371	4
2025-12-19	Henderson, Jane	Officer	Chief Financial Officer	Direct	Sale	1,500	80.00	$120,000.00	193,371	4
2025-12-10	Henderson, Michael Thomas	Director,Officer	Chief Executive Officer	Direct	Sale	20,000	75.75	$1,515,000.00	1,212,987	4
2025-12-04	Henderson, Jane	Officer	Chief Financial Officer	Direct	Sale	1,500	75.00	$112,500.00	194,871	4
2025-12-04	Dambkowski, Carl	Officer	Chief Medical Officer	Direct	Sale	10,900	75.00	$817,500.00	271,108	4
2025-12-04	Henderson, Michael Thomas	Director,Officer	Chief Executive Officer	Direct	Sale	40,000	75.01	$3,000,400.00	1,232,987	4
2025-11-25	Henderson, Jane	Officer	Chief Financial Officer	Direct	Sale	1,500	70.00	$105,000.00	196,371	4
2025-11-14	Henderson, Jane	Officer	Chief Financial Officer	Direct	Sale	2,000	65.00	$130,000.00	197,871	4
2025-11-13	Henderson, Michael Thomas	Director,Officer	Chief Executive Officer	Direct	Sale	20,000	63.37	$1,267,400.00	1,272,987	4
2025-11-11	Henderson, Jane	Officer	Chief Financial Officer	Direct	Sale	1,000	60.00	$60,000.00	199,871	4
2025-11-05	Dambkowski, Carl	Officer	Chief Medical Officer	Direct	Sale	10,785	55.14	$594,684.90	282,008	4
2025-10-01	Dambkowski, Carl	Officer	Chief Medical Officer	Direct	Sale	5,110	39.80	$203,378.00	284,733	4
2025-09-03	Dambkowski, Carl	Officer	Chief Medical Officer	Direct	Sale	2,725	38.18	$104,040.50	233,548	4
2025-08-06	Dambkowski, Carl	Officer	Chief Medical Officer	Direct	Sale	2,725	37.78	$102,950.50	236,273	4
2025-07-02	Dambkowski, Carl	Officer	Chief Medical Officer	Direct	Sale	10,090	45.51	$459,195.90	238,998	4
2025-06-04	Dambkowski, Carl	Officer	Chief Medical Officer	Direct	Sale	2,725	36.96	$100,716.00	241,723	4
2025-05-07	Dambkowski, Carl	Officer	Chief Medical Officer	Direct	Sale	2,725	35.75	$97,418.75	244,448	4
2025-04-02	Dambkowski, Carl	Officer	Chief Medical Officer	Direct	Sale	3,860	36.73	$141,777.80	247,173	4
2025-03-05	Henderson, Michael Thomas	Director,Officer	Chief Executive Officer	Direct	Sale	10,000	30.30	$303,000.00	1,292,987	4
2025-03-05	Dambkowski, Carl	Officer	Chief Medical Officer	Direct	Sale	1,590	30.48	$48,463.20	251,033	4
2025-02-05	Henderson, Michael Thomas	Director,Officer	Chief Executive Officer	Direct	Sale	15,000	40.58	$608,700.00	1,302,987	4
2025-02-05	Dambkowski, Carl	Officer	Chief Medical Officer	Direct	Sale	3,520	40.69	$143,228.80	252,623	4
2025-01-08	Henderson, Michael Thomas	Director,Officer	Chief Executive Officer	Direct	Sale	15,000	49.05	$735,750.00	1,309,487	4
2025-01-02	Dambkowski, Carl	Officer	Chief Medical Officer	Direct	Sale	4,085	47.18	$192,730.30	255,348	4
2024-12-12	Mckenna, Mark C.	Director	-	Direct	Purchase	20,000	49.44	$988,800.00	20,000	4
2024-12-11	Dambkowski, Carl	Officer	Chief Medical Officer	Direct	Sale	4,540	49.31	$223,867.40	258,073	4
2024-12-04	Henderson, Michael Thomas	Director,Officer	Chief Executive Officer	Direct	Sale	15,000	46.84	$702,600.00	1,324,487	4
2024-12-04	Dambkowski, Carl	Officer	Chief Medical Officer	Direct	Sale	6,665	46.07	$307,056.55	260,798	4
2024-11-06	Henderson, Michael Thomas	Director,Officer	Chief Executive Officer	Direct	Sale	15,000	59.56	$893,400.00	1,339,487	4
2024-11-06	Dambkowski, Carl	Officer	Chief Medical Officer	Direct	Sale	6,665	59.44	$396,167.60	267,463	4
2024-10-02	Henderson, Michael Thomas	Director,Officer	Chief Executive Officer	Direct	Sale	40,000	56.40	$2,256,000.00	1,354,487	4
2024-10-02	Dambkowski, Carl	Officer	Chief Medical Officer	Direct	Sale	6,665	56.51	$376,639.15	274,128	4
2024-09-04	Dambkowski, Carl	Officer	Chief Medical Officer	Direct	Sale	6,665	47.78	$318,453.70	280,793	4
2024-09-04	Henderson, Michael Thomas	Director,Officer	Chief Executive Officer	Direct	Sale	40,000	47.76	$1,910,400.00	1,394,487	4
2024-08-23	Henderson, Jane	Officer	Chief Financial Officer	Direct	Sale	6,000	48.26	$289,560.00	200,871	4
2024-08-07	Dambkowski, Carl	Officer	Chief Medical Officer	Direct	Sale	7,335	41.37	$303,448.95	287,458	4
2024-08-07	Henderson, Michael Thomas	Director,Officer	Chief Executive Officer	Direct	Sale	40,000	41.36	$1,654,400.00	1,434,487	4
2024-07-05	Henderson, Michael Thomas	Director,Officer	Chief Executive Officer	Direct	Sale	15,000	37.26	$558,900.00	1,474,487	4
2024-07-03	Dambkowski, Carl	Officer	Chief Medical Officer	Direct	Sale	5,995	37.72	$226,131.40	294,793	4
2023-07-13	Shah, Nimish P	Director	-	Indirect	Purchase	1,750,000	17.00	$29,750,000.00	1,750,000	4
2023-07-13	Fairmount, Funds Manageme…	Director	-	Indirect	Purchase	2,941,176	17.00	$49,999,992.00	1,992,734	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

95.35%

Inst. Shares: 66,431,969

Shares Outstanding: 69,668,439

2025-12-31

107.18%

Inst. Shares: 65,047,271

Shares Outstanding: 60,690,820

2025-09-30

99.80%

Inst. Shares: 58,657,109

Shares Outstanding: 58,773,731

2025-06-30

96.55%

Inst. Shares: 56,410,810

Shares Outstanding: 58,428,344

2025-03-31

103.30%

Inst. Shares: 60,113,815

Shares Outstanding: 58,195,272

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	66,431,969	69,668,439	95.35%
2025-12-31	65,047,271	60,690,820	107.18%
2025-09-30	58,657,109	58,773,731	99.80%
2025-06-30	56,410,810	58,428,344	96.55%
2025-03-31	60,113,815	58,195,272	103.30%
2024-12-31	56,232,928	55,193,971	101.88%
2024-09-30	54,908,477	56,795,544	96.68%
2024-06-30	53,242,833	56,515,003	94.21%
2024-03-31	52,173,426	50,189,808	103.95%
2023-12-31	40,914,598	25,005,774	163.62%
2023-09-30	37,858,548	41,231,379	91.82%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Apogee Therapeutics, Inc. (APGE) — SEC Financial Statements & Analysis

Apogee Therapeutics, Inc. (APGE) is a biological products, (no diagnostic substances) company. Apogee Therapeutics, Inc. trades on APGE: Nasdaq as: APGE. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), Apogee Therapeutics, Inc. reported a Debt-to-Equity ratio of 0.03x, a Price-to-Book (P/B) ratio of 4.67 (TTM), at a market cap of $5.86B. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.03x
P/B TTM: 4.67
Market Cap: $5.86B

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Apogee Therapeutics, Inc. in?

Apogee Therapeutics, Inc. (APGE) operates in the Biological Products, (No Diagnostic Substances) industry.

What is APGE's market cap?

Apogee Therapeutics, Inc. (APGE) has a market capitalization of $5.86B as of 2026-03-31.

What exchange does APGE trade on?

Apogee Therapeutics, Inc. (APGE) trades on the APGE: Nasdaq.

Apogee Therapeutics, Inc. (APGE) — SEC Financial Statements & Analysis

Frequently Asked Questions

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.